Great West Life Assurance CO Arcus Biosciences, Inc. Transaction History

Great West Life Assurance CO

$58 Billion
Q4 2024

A detailed history of Great West Life Assurance CO transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 52,150 shares of RCUS stock, worth $468,828. This represents 0.0% of its overall portfolio holdings.

Number of Shares

52,150

Previous 52,150 -0.0%

Holding current value

$468,828

Previous $798,000 2.88%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$13.69 - $18.01 $91,750 - $120,703	-6,702 Reduced 11.39%	52,150 $798,000
Q2 2024 Aug 12, 2024	BUY	$14.59 - $18.48 $181,295 - $229,632	12,426 Added 26.77%	58,852 $895,000
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $16,421 - $21,939	932 Added 2.05%	46,426 $834,000
Q2 2023 Aug 10, 2023	SELL	$16.97 - $22.03 $54,965 - $71,355	-3,239 Reduced 6.65%	45,494 $924,000
Q1 2023 May 12, 2023	SELL	$15.96 - $23.15 $67,383 - $97,739	-4,222 Reduced 7.97%	48,733 $888,000
Q4 2022 Feb 10, 2023	SELL	$19.7 - $35.71 $74,820 - $135,626	-3,798 Reduced 6.69%	52,955 $1.1 Million
Q3 2022 Nov 01, 2022	BUY	$23.23 - $30.07 $1.32 Million - $1.71 Million	56,753 New	56,753 $1.48 Million
Q2 2022 Aug 09, 2022	BUY	$17.23 - $37.73 $745,266 - $1.63 Million	43,254 Added 2381.83%	45,070 $1.14 Million
Q1 2022 May 12, 2022	SELL	$28.92 - $41.83 $20,070 - $29,030	-694 Reduced 27.65%	1,816 $61,000
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $27,232 - $43,086	-1,041 Reduced 29.32%	2,510 $70,000
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $31,807 - $60,545	1,871 Added 111.37%	3,551 $92,000
Q3 2020 Nov 17, 2020	SELL	$17.14 - $25.47 $1.67 Million - $2.48 Million	-97,304 Reduced 98.3%	1,680 $28,000
Q3 2020 Nov 13, 2020	BUY	$17.14 - $25.47 $1.67 Million - $2.48 Million	97,304 Added 5791.9%	98,984 $1.7 Million
Q2 2020 Aug 17, 2020	BUY	$13.97 - $36.56 $17,490 - $45,773	1,252 Added 292.52%	1,680 $41,000
Q4 2019 Feb 11, 2020	BUY	$7.33 - $10.79 $3,137 - $4,618	428 New	428 $4,000
Q3 2019 Oct 25, 2019	SELL	$6.44 - $10.18 $31,916 - $50,452	-4,956 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$9.74 - $14.5 $48,271 - $71,862	4,956 New	4,956 $51,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $649M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.

Account

Great West Life Assurance CO Arcus Biosciences, Inc. Transaction History